Abstract
Targeted therapy has emerged as a revolutionary approach in oncology, offering personalized and precision-based interventions that improve survival and quality of life. Unlike traditional chemotherapy, which indiscriminately attacks both healthy and cancerous cells, targeted therapies hone in on specific molecular markers involved in tumor growth and progression. This article explores the advancements, clinical applications, and future trends of targeted therapy in oncology. We analyze the roles of biomarkers, resistance mechanisms, combination regimens, and technological innovations like AI and CRISPR in guiding next-generation targeted treatments. The paper also discusses regulatory, ethical, and financial considerations shaping future clinical integration.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2021 Dr. Amna Farooq (Author)